Dylan D Thomas1,2, Molly E Waring3, Omid Ameli1, Joel I Reisman1, Varsha G Vimalananda1,2. 1. Center for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, Massachusetts, USA. 2. Section of Endocrinology, Diabetes, Nutrition, and Weight Management, Department of Medicine, School of Medicine, Boston University, Boston, Massachusetts, USA. 3. Department of Allied Health Sciences, University of Connecticut, Storrs, Connecticut, USA.
Abstract
OBJECTIVE: Weight-management medications (WMM) are recommended for the treatment of obesity. This study examined characteristics associated with initial receipt of WMM among eligible veterans in the first year following enrollment in the Veterans Health Administration (VHA) MOVE! behavioral weight-management program. METHODS: We conducted a retrospective cohort study of VHA patients with obesity or overweight and obesity-related comorbidities who enrolled in MOVE! from October 2013 to September 2016 (N = 153,939). Multivariable logistic regression models estimated predictors of having a filled prescription for WMM and for orlistat. RESULTS: A total of 1.1% of these veterans received WMM. The most common WMM included orlistat (70.4%), phentermine/topiramate (11.2%), and bupropion/naltrexone (9.7%). Female sex, higher BMI, obstructive sleep apnea, osteoarthritis, depression, lower back pain, and alcohol abuse were associated with greater odds of use of WMM, whereas age over 65 years, Hispanic ethnicity, and required co-payments were associated with lower odds. Among patients receiving WMM, older age, black race, female sex, higher BMI, cardiovascular disease, lower back pain, and congestive heart failure were associated with use of orlistat versus any other WMM. CONCLUSIONS: Of patients engaged in MOVE! in the VHA, 1.1% received WMM. WMM are underutilized among veterans. Additional research is needed to understand barriers to incorporating WMM into comprehensive obesity treatment plans.
OBJECTIVE: Weight-management medications (WMM) are recommended for the treatment of obesity. This study examined characteristics associated with initial receipt of WMM among eligible veterans in the first year following enrollment in the Veterans Health Administration (VHA) MOVE! behavioral weight-management program. METHODS: We conducted a retrospective cohort study of VHA patients with obesity or overweight and obesity-related comorbidities who enrolled in MOVE! from October 2013 to September 2016 (N = 153,939). Multivariable logistic regression models estimated predictors of having a filled prescription for WMM and for orlistat. RESULTS: A total of 1.1% of these veterans received WMM. The most common WMM included orlistat (70.4%), phentermine/topiramate (11.2%), and bupropion/naltrexone (9.7%). Female sex, higher BMI, obstructive sleep apnea, osteoarthritis, depression, lower back pain, and alcohol abuse were associated with greater odds of use of WMM, whereas age over 65 years, Hispanic ethnicity, and required co-payments were associated with lower odds. Among patients receiving WMM, older age, black race, female sex, higher BMI, cardiovascular disease, lower back pain, and congestive heart failure were associated with use of orlistat versus any other WMM. CONCLUSIONS: Of patients engaged in MOVE! in the VHA, 1.1% received WMM. WMM are underutilized among veterans. Additional research is needed to understand barriers to incorporating WMM into comprehensive obesity treatment plans.
Authors: Amy S B Bohnert; Mark A Ilgen; Robert M Bossarte; Peter C Britton; Stephen T Chermack; Frederic C Blow Journal: Mil Med Date: 2012-02 Impact factor: 1.437
Authors: Susan D Raffa; Matthew L Maciejewski; Lindsey E Zimmerman; Laura J Damschroder; Paul A Estabrooks; Ronald T Ackermann; Adam G Tsai; Trina Histon; Michael G Goldstein Journal: J Gen Intern Med Date: 2017-04 Impact factor: 5.128
Authors: Gary D Foster; Thomas A Wadden; Angela P Makris; Duncan Davidson; Rebecca Swain Sanderson; David B Allison; Amy Kessler Journal: Obes Res Date: 2003-10
Authors: W Timothy Garvey; Jeffrey I Mechanick; Elise M Brett; Alan J Garber; Daniel L Hurley; Ania M Jastreboff; Karl Nadolsky; Rachel Pessah-Pollack; Raymond Plodkowski Journal: Endocr Pract Date: 2016-05-24 Impact factor: 3.443
Authors: Todd P Semla; Chris Ruser; Chester B Good; Susan Z Yanovski; Donna Ames; Laurel A Copeland; Charles Billington; U Inge Ferguson; Louis J Aronne; Thomas A Wadden; W Timothy Garvey; Caroline M Apovian; David Atkins Journal: J Gen Intern Med Date: 2017-04 Impact factor: 5.128
Authors: Jay Pendse; Franco Vallejo-García; Andrew Parziale; Mae Callanan; Craig Tenner; José O Alemán Journal: Obesity (Silver Spring) Date: 2021-02 Impact factor: 5.002
Authors: Katherine D Hoerster; Margaret P Collins; David H Au; Amber Lane; Eric Epler; Jennifer McDowell; Anna E Barón; Peter Rise; Robert Plumley; Tanya Nguyen; Mary Schooler; Linnaea Schuttner; Jun Ma Journal: Contemp Clin Trials Date: 2020-05-28 Impact factor: 2.226